A professor at the University of Paris School of Medicine, Gregory Katz holds the Chair of Innovation & Value in Health. His research activities focus on patient-reported outcomes and the impact of transparent benchmarks on clinical practices. He is the Academic Director of the European Union report entitled Implementing Value-Based Health Care in Europe: Handbook for Pioneers (2020). Between 2006 and 2019, Katz was the Director of research and innovation in two leading private hospital groups in Europe. He is the Founder of the VBHC Consortium, a nonprofit dedicated to accelerating the emergence of Value-Based Health Care (VBHC) to enable medical teams to compare and improve patient outcomes. Since 2020, he is also President of PromTime, a company specialized in implementing outcome-driven ecosystems. From 2003-2005, Katz was a Visiting Professor at INSEAD (Singapore). From 2004 to 2015, he was a Professor at ESSEC Business School (Paris-Singapore), Chair of Therapeutic Innovation, and Co-director of the Institute for Health Economics & Management. His pro bono activities include Vice-President of the Eurocord (2004-2008), a nonprofit conducting clinical research on cord blood transplantation across 56 countries. He was Chairman of the Scientific Board of the GlaxoSmithKline Vaccines Global Innovation Fund (2012-2015), Chairman of the think tank Digital Leaders in Health (2018), and Senior fellow of the U.S. Center for Medicine in the Public Interest. Since 2020, Katz is an elected member of the French National Academy of Surgery. He is the recipient of several awards, including the San Benedetto International Prize for his achievements in bioethics and humanism (2009), the Special Jury Award from the French Fédération de l’Hospitalisation Privée (2012), and was guest of honor of the Grand Rounds Lecture at the UCLA Fielding School of Public Health (2015). In 2020, the French Ministry of Health and the national payer - the Assurance Maladie - commissioned Prof. Katz and his team to implement the first VBHC experiment on cataracts to incentivize practitioners on patient outcomes.
Peter Pitts is President of the Center for Medicine in the Public Interest. He is a former member of the United States Senior Executive Service and Associate Commissioner of the US Food & Drug Administration. Pitts is a member of the Council for International Organizations of Medical Sciences (CIOMS is a NGO established jointly by WHO and UNESCO in 1949) Expert Working Group to help advance patient involvement in the development and safe use of medicines. He is the lead author of many peer reviewed publications including the Lancet and Nature Biotechnology. He is an Associate Editor of Therapeutic Innovation & Regulatory Science (official DIA journal), a member of the External Advisory Board, IMS Institute for Healthcare Informatics in Asia, Executive Advisory Board, the Galien Foundation, Editorial Advisory Board, Food and Drug Policy Forum, Advisory Board, Journal of Commercial Biotechnology and the Editorial Advisory Board, The Patient Magazine. Pitts lives in New York City.
Only students from University of Paris School of Medicine are eligible to apply. The Chair welcomes medical students (years 4, 5, 6 and residents), PharmD and PhD students, master students, and students from university exchange programs (Erasmus, etc.). The application process involves the following steps:
+33 1 53 10 47 03
University of Paris School of Medicine
Chair of Innovation & Value in Health
15, rue de l’Ecole de Médecine 75006 Paris, France